Riluzole

Generic Name: Riluzole

Brand Names: Exservan, Rilutek, Tiglutik, Riluzole Zentiva

Drug Type: Small Molecule

Chemical Formula: C_₈H_₅F_₃N_₂OS

CAS Number: 1744-22-5

Unique Ingredient Identifier: 7LJ087RS6F

Background: A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi.

Indication: For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)

Associated Conditions: Amyotrophic Lateral Sclerosis (ALS)

Associated Therapies: -

Clinical Trials

Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect)

Phase 3

Completed

Conditions: Cervical Spondylotic Myelopathy

Interventions: Drug: Placebo medication
Drug: riluzole

First Posted Date: 2010-12-10

Last Posted Date: 2018-11-02

Lead Sponsor: AOSpine North America Research Network

Target Recruit Count: 270

Registration Number: NCT01257828

Locations: 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸
Louisiana State University, Baton Rouge, Louisiana, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 18 locations

Efficacy and Tolerability of Riluzole in Treatment Resistant Depression

Phase 2

Completed

Conditions: Depression

Interventions: Drug: placebo
Drug: Riluzole

First Posted Date: 2010-09-17

Last Posted Date: 2020-03-06

Lead Sponsor: Yale University

Target Recruit Count: 104

Registration Number: NCT01204918

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Yale University, Yale Depression Research Program, New Haven, Connecticut, United States
🇺🇸
Massachussettes General Hospital, Depression Clinical and Research Center, Boston, Massachusetts, United States

Efficacy of Riluzole in Hereditary Cerebellar Ataxia

Phase 2

Completed

Conditions: Cerebellar Ataxia

Interventions: Drug: Placebo comparator
Drug: riluzole

First Posted Date: 2010-04-15

Last Posted Date: 2015-04-21

Lead Sponsor: S. Andrea Hospital

Target Recruit Count: 60

Registration Number: NCT01104649

Locations: 🇮🇹
Center for Experimental Neurological Therapies (CENTERS), S. Andrea Hospital, II Faculty of Medicine, "Sapienza" University of Rome, Rome, Italy

Riluzole and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Phase 1

Terminated

Conditions: Metastatic Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: riluzole
Radiation: whole-brain radiation therapy

First Posted Date: 2009-11-25

Last Posted Date: 2014-05-02

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 9

Registration Number: NCT01018836

Locations: 🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission

Phase 4

Completed

Conditions: Tourette Syndrome

Interventions: Drug: Placebo
Drug: D-serine
Drug: Riluzole

First Posted Date: 2009-11-23

Last Posted Date: 2018-01-30

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 39

Registration Number: NCT01018056

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer

Phase 1

Withdrawn

Conditions: Breast Cancer

First Posted Date: 2009-05-18

Last Posted Date: 2013-04-29

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT00903214

Riluzole in Fragile X Syndrome

Phase 4

Completed

Conditions: Fragile X Syndrome

Interventions: Drug: Riluzole

First Posted Date: 2009-05-08

Last Posted Date: 2017-04-18

Lead Sponsor: Indiana University

Target Recruit Count: 6

Registration Number: NCT00895752

Locations: 🇺🇸
Riley Child and Adolescent Psychiatry Clinic - Riley Hospital for Children, Indianapolis, Indiana, United States

Safety of Riluzole in Patients With Acute Spinal Cord Injury

Completed

Conditions: Spinal Cord Injury

First Posted Date: 2009-04-07

Last Posted Date: 2017-09-12

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 36

Registration Number: NCT00876889

Locations: 🇺🇸
The University of Texas, Houston, Texas, United States
🇺🇸
University of Virginia Health System, Charlottesville, Virginia, United States
🇺🇸
University of Louisville Health Sciences Center, Louisville, Kentucky, United States

and more 5 locations

Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS

Phase 3

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Olesoxime
Drug: Placebo Comparator
Drug: Riluzole

First Posted Date: 2009-03-24

Last Posted Date: 2020-02-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 512

Registration Number: NCT00868166

Locations: 🇧🇪
University Hospital Gasthuisberg - Dept Neurology - Herestraat 49, Leuven, Belgium
🇫🇷
Hôpital La Timone - Service Neurologie et Maladies Neuromusculaires, Marseille, France
🇫🇷
Clinique du Motoneurone - Sce d'Explorations Neurologiques - Hôpital Gui de Chauliac, Montpellier, France

and more 12 locations

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Melanoma (Skin)

Interventions: Drug: riluzole

First Posted Date: 2009-03-23

Last Posted Date: 2024-01-19

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 13

Registration Number: NCT00866840

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy